
Cytokinetics (NASDAQ:CYTK) executives said the company is seeing momentum in the launch of heart drug MYQORZO and is preparing to seek U.S. approval for its use in a second form of hypertrophic cardiomyopathy.
Speaking at the UBS Biopharma Conference, President and CEO Robert Blum also announced that the U.S. Food and Drug Administration had approved an expanded MYQORZO label incorporating data from the MAPLE-HCM study, which compared aficamten, the drug’s active ingredient, with the beta blocker metoprolol.
Blum said the original label, based on the SEQUOIA study, already covered patients with obstructive hypertrophic cardiomyopathy, or oHCM, whether or not they were taking beta blockers. He described the MAPLE addition as incremental, but said it provides data in the label supporting consideration of MYQORZO as an alternative to a beta blocker.
Prescriber Growth and Payer Requirements
Blum said Cytokinetics is seeking to expand the cardiac myosin inhibitor category while increasing its share of new prescriptions. He estimated that more than 80% of symptomatic patients diagnosed with oHCM in the U.S. are not receiving a drug in the category, which includes Bristol Myers Squibb’s CAMZYOS.
Chief Commercial Officer Andrew Callos said more than 70% of market growth in the third quarter came from physicians who had not previously prescribed a cardiac myosin inhibitor. Cytokinetics is discussing MYQORZO with about 11,000 U.S. physicians who treat and diagnose hypertrophic cardiomyopathy, while approximately 2,500 physicians currently prescribe drugs in the category, he said.
Callos said the overall market grew about 50% in the first nine months of the year compared with the same period a year earlier. He expects continued growth as more physicians begin prescribing the drugs.
Payers generally require patients to try a beta blocker first or physicians to attest that one has been tried or cannot be taken, Callos said. While requirements could loosen as evidence and guidelines evolve, he said he did not expect that to happen in the next one to two years.
Fady Malik, executive vice president of research and development, said he expects clinical guidelines to be updated in 2027 to reflect newer trial data. Blum said physicians may move patients through beta-blocker requirements more quickly in the meantime.
International Launch and Monitoring
MYQORZO is available in China and Germany, with a U.K. launch planned for the current quarter, Blum said. Callos said France is expected to launch in the first quarter, with eight additional European launches expected next year.
In Germany, MYQORZO has achieved more than 50% of new-to-brand prescriptions for three consecutive months, Callos said. He estimated that Europe could account for about 15% of overall revenue a few years out, reflecting lower pricing than in the U.S.
Executives also discussed their plans to gather real-world evidence that could support changes to the drug’s FDA risk evaluation and mitigation strategy, or REMS. Callos said a data review showed that 50% of patients on a maintenance dose were taking 5 milligrams and 30% were taking 10 milligrams.
Malik said the company hopes eventually to discuss rolling back some REMS requirements with the FDA, potentially in stages. He said there was no specific threshold for approaching the agency and that a timeframe of a couple of years or longer was difficult to pin down.
Non-Obstructive Filing and Capital
Malik said Cytokinetics remains on track to submit a supplemental application this quarter seeking approval based on the ACACIA study in non-obstructive hypertrophic cardiomyopathy, or nHCM. If the review proceeds favorably, he said, the company hopes for approval by around the same time next year.
Callos said physicians experienced with cardiac myosin inhibitors have told the company that some patients are waiting for treatment if the drug is approved for nHCM. The company is preparing disease-awareness and marketing efforts for a potential launch, he said.
Chief Financial Officer Sung Lee said Cytokinetics had $1.6 billion on its balance sheet at the end of the last quarter. He said the company plans to allocate capital to the commercial launches and its drug pipeline. Blum added that the company expects to have more to say about its pipeline in 2027.
About Cytokinetics (NASDAQ:CYTK)
Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.
